{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:17:23Z","timestamp":1791400643664,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00280-010-1265-5","type":"journal-article","created":{"date-parts":[[2010,2,17]],"date-time":"2010-02-17T04:02:05Z","timestamp":1266379325000},"page":"1079-1085","source":"Crossref","is-referenced-by-count":66,"title":["A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies"],"prefix":"10.1007","volume":"66","author":[{"given":"Paul K.","family":"Paik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalyn","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Markus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Subzwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(03)01277-4","volume":"4","author":"W Hu","year":"2003","unstructured":"Hu W, Kavanagh JJ (2003) Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4:721\u2013729","journal-title":"Lancet Oncol"},{"key":"1265_CR2","doi-asserted-by":"crossref","unstructured":"Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324\u20131337","DOI":"10.1038\/sj.onc.1210220"},{"key":"1265_CR3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nrc1736","volume":"5","author":"SW Fesik","year":"2005","unstructured":"Fesik SW (2005) Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5:876\u2013885","journal-title":"Nat Rev Cancer"},{"key":"1265_CR4","unstructured":"GeminX I (2006) Investigator\u2019s brochure GX15-070MS. Malvern, PA"},{"key":"1265_CR5","doi-asserted-by":"crossref","unstructured":"Perez-Galan P, Roue G, Villamor N (2006) The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib, AACR, pp A575","DOI":"10.1182\/blood.V106.11.1490.1490"},{"key":"1265_CR6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-007-0499-3","volume":"61","author":"J Li","year":"2008","unstructured":"Li J, Viallet J, Haura E (2008) A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol 61:525\u2013534","journal-title":"Cancer Chemother Pharmacol"},{"key":"1265_CR7","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2005.03.3332","volume":"24","author":"JR Eckardt","year":"2006","unstructured":"Eckardt JR, von Pawel J, Papai Z et al (2006) Open-label, multicenter, randomized, phase III study comparing oral topotecan\/cisplatin versus etoposide\/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24:2044\u20132051","journal-title":"J Clin Oncol"},{"key":"1265_CR8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000217998","volume":"17","author":"M Higashiyama","year":"1996","unstructured":"Higashiyama M, Doi O, Kodama K et al (1996) Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer. Tumour Biol 17:341\u2013344","journal-title":"Tumour Biol"},{"key":"1265_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","volume":"177","author":"S Jiang","year":"1995","unstructured":"Jiang S, Sato Y, Kuwao S et al (1995) Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135\u2013138","journal-title":"J Pathol"},{"key":"1265_CR10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-003-0763-9","volume":"442","author":"E Fokkema","year":"2003","unstructured":"Fokkema E, de Vries E, Groen H et al (2003) Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. Virchows Arch 442:349\u2013355","journal-title":"Virchows Arch"},{"key":"1265_CR11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ijc.10096","volume":"97","author":"U Sartorius","year":"2002","unstructured":"Sartorius U, Krammer P (2002) Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584\u2013592","journal-title":"Int J Cancer"},{"key":"1265_CR12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1093\/jnci\/89.14.1027","volume":"89","author":"A Ziegler","year":"1997","unstructured":"Ziegler A, Luedke GH, Fabbro D et al (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89:1027\u20131036","journal-title":"J Natl Cancer Inst"},{"key":"1265_CR13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/bjc.1998.624","volume":"78","author":"U Zangemeister-Wittke","year":"1998","unstructured":"Zangemeister-Wittke U, Schenker T, Luedke G et al (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035\u20131042","journal-title":"Br J Cancer"},{"key":"1265_CR14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.onc.1208997","volume":"25","author":"YH Kim","year":"2005","unstructured":"Kim YH, Girard L, Giacomini CP et al (2005) Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25:130\u2013138","journal-title":"Oncogene"},{"key":"1265_CR15","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","volume":"14","author":"AD Schimmer","year":"2008","unstructured":"Schimmer AD, O\u2019Brien S, Kantarjian H et al (2008) A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 14:8295\u20138301","journal-title":"Clin Cancer Res"},{"key":"1265_CR16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0169-5002(00)80136-1","volume":"20","author":"R Koschel","year":"2000","unstructured":"Koschel R, Huber R, Gatzmeier U (2000) Toptecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy. Lung Cancer 20:42","journal-title":"Lung Cancer"},{"key":"1265_CR17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1183\/09031936.06.00015605","volume":"27","author":"RM Huber","year":"2006","unstructured":"Huber RM, Reck M, Gosse H et al (2006) Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 27:1183\u20131189","journal-title":"Eur Respir J"},{"key":"1265_CR18","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1200\/JCO.1996.14.10.2785","volume":"14","author":"R Perez-Soler","year":"1996","unstructured":"Perez-Soler R, Glisson BS, Lee JS et al (1996) Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785\u20132790","journal-title":"J Clin Oncol"},{"key":"1265_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","volume":"113","author":"SM O\u2019Brien","year":"2009","unstructured":"O\u2019Brien SM, Claxton DF, Crump M et al (2009) Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299\u2013305","journal-title":"Blood"},{"key":"1265_CR20","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421\u20133428","journal-title":"Cancer Res"},{"key":"1265_CR21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI et al (2007) Programmed anuclear cell death delimits platelet life span. Cell 128:1173\u20131186","journal-title":"Cell"},{"key":"1265_CR22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402072","volume":"14","author":"H Zhang","year":"2007","unstructured":"Zhang H, Nimmer PM, Tahir SK et al (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14:943\u2013951","journal-title":"Cell Death Differ"},{"key":"1265_CR23","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1200\/jco.2009.27.15_suppl.3505","volume":"27","author":"A Roberts","year":"2009","unstructured":"Roberts A, Wilson W, Gandhi L et al (2009) Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol 27:3505 (abstr)","journal-title":"J Clin Oncol"},{"key":"1265_CR24","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1200\/jco.2009.27.15_suppl.8574","volume":"27","author":"W Wilson","year":"2009","unstructured":"Wilson W, O\u2019Connor O, Roberts A (2009) ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL). J Clin Oncol 27:8574 (abstr)","journal-title":"J Clin Oncol"},{"key":"1265_CR25","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","volume":"104","author":"M Nguyen","year":"2007","unstructured":"Nguyen M, Marcellus RC, Roulston A et al (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104:19512\u201319517","journal-title":"Proc Natl Acad Sci USA"},{"key":"1265_CR26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/1535-7163.MCT-08-1118","volume":"8","author":"P Hauck","year":"2009","unstructured":"Hauck P, Chao BH, Litz J et al (2009) Alterations in the Noxa\/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther 8:883\u2013892","journal-title":"Mol Cancer Ther"},{"key":"1265_CR27","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/jco.2009.27.15_suppl.3576","volume":"27","author":"A Chiappori","year":"2009","unstructured":"Chiappori A, Schreeder M, Moezi M (2009) A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol 27:3576 (abstr)","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1265-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1265-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1265-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T03:04:43Z","timestamp":1634958283000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1265-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,18]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1265-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,18]]}}}